A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Latest Information Update: 21 Nov 2025
At a glance
- Drugs Cisplatin (Primary) ; Hafnium oxide (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms LUMIRAY
- Sponsors Johnson & Johnson
Most Recent Events
- 18 Nov 2025 Planned initiation date changed from 7 Jan 2026 to 11 Dec 2025.
- 27 Oct 2025 New trial record